17,261 trials
Crohn's Disease
Primary: The Crohn's Disease Activity Index (CDAI)-70 Response Rate at Week 8 in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg — 30.6; 35.0; 49.3…
Lung Cancer
Primary: Overall Objective Response — 1; 1; 3; 2 participants
Dietary Carcinogenesis
Primary: AFB1-lysine Adduct (pg/mg) Overtime — 3.77; 4.09; 4.26; 3.00 pg/mg albumin
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
Compensated Cirrhosis and Portal Hypertension
Primary: Change From Baseline of the Blood Flow for the Total Renal Arteries (Study Part A (Serelaxin Treatment Group Only)) — 0.438 L/min
Osteosarcoma
Primary: Radiographic Response — 21; 5; 5; 3 participants
Non-small Cell Lung Cancer Metastatic
Primary: Progression-Free Survival (PFS) — 5.22; 4.21 Months
Ovarian Cancer · Primary PERITONEUM · Fallopian Tube Cancer
Primary: Overall Objective Response — 10; 13; 11; 4 participants
Epilepsy · Seizures · Bipolar Disorder
Primary: Area Under the Curve (AUC) for Oral Bioavailability of Lamotrigine (LTG — 142.8; 132.3 µg*h/mL
Diabetes Mellitus, Type 1
Primary: Change in Metabolic Function Baseline to 12 Months. — 0.74; 0.43 nmol/L/min — p=0.017
Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer
Primary: Overall Objective Response of OSI-774 — 1; 18; 31; 30 participants
Colorectal Neoplasms
Primary: Progression Free Survival (PFS) Rate as Measured at Week 8 — 20; 20 percentage of participants
Stage IIB Breast Cancer · Stage IIIA Breast Cancer · Stage IIIB Breast Cancer
Primary: %Change in FLT Uptake Between the Baseline (Pre-therapy) and the Early-therapy Imaging Studies to Predict Pathological Complete Response — 38.78 percentage change of…
Healthy
Primary: Physical Function (CS-PFP Total Score) — 3.1; 3.6; 0.8; 3.3 units on a scale — p=<0.025
Adult Malignant Fibrous Histiocytoma of Bone · Desmoid Tumor · Endometrial Cancer
Primary: Overall Objective Response — 1; 21; 26 participants